Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.0%

1 terminated out of 50 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

10%

5 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed with results

Key Signals

2 with results89% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (17)
P 1 (2)
P 2 (4)
P 3 (2)
P 4 (3)

Trial Status

Recruiting23
Not Yet Recruiting11
Completed8
Active Not Recruiting5
Enrolling By Invitation1
Terminated1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (50)

Showing 20 of 20 trials
NCT07083557Recruiting

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT06595420Recruiting

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

NCT06823115Enrolling By Invitation

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

NCT06906640Not ApplicableRecruitingPrimary

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT06906627Not ApplicableRecruitingPrimary

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

NCT06754280Not ApplicableRecruitingPrimary

An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease

NCT06819527Not ApplicableCompletedPrimary

Medication Reconciliation in Hospitalized CKD Patients : A Quasi-Experimental Study

NCT06781294Not ApplicableActive Not Recruiting

SIRAKI 02 Posthoc Analysis.

NCT06841016Not ApplicableCompletedPrimary

Virtual Nephrologist

NCT06818305Phase 2Terminated

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

NCT06698614Recruiting

MEMRI and Kidney Disease

NCT05732727Phase 3RecruitingPrimary

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

NCT07239570Phase 4RecruitingPrimary

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

NCT07030595Phase 3Completed

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

NCT07173062Not ApplicableRecruiting

Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome

NCT06655181Not ApplicableCompletedPrimary

Evaluating the Effectiveness of Respiratory Muscle Training in Pediatric Kidney Transplant Patient

NCT07043166Recruiting

Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens

NCT07127068Not ApplicableActive Not Recruiting

Investigation of the Effects of Omega-3 Supplementation in Chronic Kidney Disease Patients Diagnosed With Coronary Artery Disease and Dyslipidemia

NCT06962891Active Not RecruitingPrimary

Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease

NCT06940414Recruiting

Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community

Scroll to load more

Research Network

Activity Timeline